• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Nearly 900 new drugs in R&D for diseases affecting women

Nearly 900 new drugs in R&D for diseases affecting women

May 17, 2011
CenterWatch Staff

A new industry report published by U.S. drugmakers states that almost 900 medicines are in development for diseases specifically affecting women, according to Pharma Times.

The drugs are either in clinical trials or awaiting FDA approval or review and include the following: 139 potential treatments for cancers affecting women including 91 for breast cancer and 49 for ovarian cancer and nine for cervical cancer, says the Pharmaceutical Research and Manufacturers of America (PhRMA) report.

Additionally, 114 potential new treatments for arthritis and musculoskeletal disorders are in development,  noting that 60% of U.S. arthritis patients are female; there are 83 new treatments are in R&D for Alzheimer's disease and 72 for depression and anxiety, which affect almost twice as many women than men.

Diseases that affect more women such as multiple sclerosis and rheumatoid arthritis have 110 treatments in R&D, and 64 are being developed for obstetric and gynecological conditions. Researchers are also working on 299 medications for cardiac conditions, which cause death in nearly 500,000 women in the U.S. every year, and 98 medicines for lung cancer, the leading cancer-killer of women.

"As recently as a couple of decades ago, there was a basic assumption that what was good medically for men was good for women in almost every case," said PhRMA chief executive John Castellani. "Today, our increasing knowledge of the less-obvious differences between man and women is providing great promise for new and better treatments that will benefit both sexes," he added.

 

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing